Keith Thompson (CGT) announces the creation of Islexa

On day 1 of the World Stem Cells & Regenerative Medicine Congress, Keith Thompson, CEO of the Cell and Gene Therapy Catapult, announced, in partnership with the University of Aberdeen, the creation of a new company: Islexa. Islexa is developing an innovative method to produce laboratory grown islets, which are the organoids in charge of insulin production. This technology holds …